Key Points
- CEO Jack Bendheim sold 3,651 shares on Jan. 14 at an average price of $40.53, leaving him with 47,457 shares (a 7.14% reduction) valued at roughly $1.92 million.
- Pattern of insider sales: Bendheim has sold repeatedly since late November, generating about $1.7 million in proceeds across the reported trades through Jan. 15.
- Company snapshot: Phibro has a $1.62 billion market cap, a P/E of ~24.1 and a 52-week range of $16.16–$46.42, after a recent quarterly EPS beat and FY2026 guidance of 2.64–2.81; the stock yields about 1.2%.
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 2,932 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64. Following the transaction, the chief executive officer owned 44,525 shares in the company, valued at approximately $1,781,890.50. This trade represents a 6.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jack Bendheim also recently made the following trade(s):
- On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total transaction of $147,975.03.
- On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
- On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
- On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
- On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
- On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
- On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total value of $141,011.20.
- On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total value of $143,510.40.
- On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.93, for a total transaction of $309,267.20.
- On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.02, for a total transaction of $232,425.60.
Phibro Animal Health Price Performance
PAHC stock opened at $40.06 on Friday. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $46.42. The firm has a market cap of $1.62 billion, a P/E ratio of 24.13, a PEG ratio of 1.13 and a beta of 0.79. The stock's 50 day moving average price is $40.65 and its 200 day moving average price is $36.92. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.35 and a current ratio of 3.09.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.
Phibro Animal Health Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health's payout ratio is 28.92%.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on PAHC. Weiss Ratings reissued a "buy (b-)" rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. boosted their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an "overweight" rating in a report on Friday, November 7th. Finally, Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $31.40.
Check Out Our Latest Analysis on Phibro Animal Health
Hedge Funds Weigh In On Phibro Animal Health
A number of hedge funds have recently made changes to their positions in PAHC. Geode Capital Management LLC grew its position in shares of Phibro Animal Health by 1.4% during the second quarter. Geode Capital Management LLC now owns 554,927 shares of the company's stock worth $14,175,000 after buying an additional 7,841 shares in the last quarter. Millennium Management LLC raised its stake in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock valued at $7,733,000 after purchasing an additional 154,281 shares in the last quarter. Ranger Investment Management L.P. lifted its position in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company's stock worth $9,143,000 after purchasing an additional 179,975 shares during the last quarter. Invesco Ltd. grew its stake in Phibro Animal Health by 22.5% in the third quarter. Invesco Ltd. now owns 322,299 shares of the company's stock worth $13,040,000 after purchasing an additional 59,226 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Phibro Animal Health by 9.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 301,605 shares of the company's stock valued at $12,203,000 after buying an additional 26,539 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.
The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
